AIM Breakfasts

AIM BREAKFAST – 10th August 2016

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 1,008

Total number of AIM Companies trading: 992*
* As at 08 August 2016

Dish of the Day:

Shares in TBC Bank Group , a leading bank in Georgia, expected to start trading on  main market under a premium listing  (TBCG.L)

Off the Menu:

No leavers today

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): *

Total number of ISDX Growth Market Companies trading: *
* As at 08 August 2016

Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?

LoopUp—The provider of conference calls and online meetings is seeking to join AIM. 2015 revs of £9.2m and EBITDA of £1.02m

Bacanora Lithium— To list on AIM as holding company for TSX listed Bacanora Minerals at £100m market cap

Aura Energy—ASX listed uranium developer (ASX:AEE) expected to join AIM 6 September

Autins Group plc – The acoustic and thermal insulation specialist now looks to join AIM late August

 

Breakfast Buffet

Conroy Gold & Natural Resources* (CGNR.L) 32p £3.5m

The gold exploration and development company  has announced that an independent structural study  has confirmed the continuity of the gold lodes at the Company’s Clontibret gold target. Continuity of Lode Confirmed Over 50 Metres. This demonstration of the continuity of the gold mineralisation at Clontibret is a further essential step forward as the Company proceeds with its Clay Lake-Clontibret gold mining project.

 

CloudTag (CTAG.L) 5.5p £18.9m

The company that brings personal monitoring to the wellbeing, fitness and digital health market has announced a £580k fundraise at 5.8p, a premium of 5.45% to yesterday’s close. The proceeds of the Subscription will be used for general working capital purposes.  In addition, certain trade creditors of the Company have agreed that their outstanding invoices totalling £268,000 in respect to professional advisory services can be settled in shares.

 

MidaTech Pharma (MTPH.L) 113.5p £38.1m

The international specialty pharmaceutical company focused on commercialising and developing products in oncology, immunology and other therapeutic areas, has issued an H1 Jun 2016 trading  update. Revenues of £3.80m, up from £0.32m in line with expectations. Positive advances at Midatech include launching Zuplenz® in the US to provide relief from one of the most debilitating side-effects of common cancer treatments, nausea and vomiting.

 

Share (SHRE.L) 28.25p £40.58m

The parent company of The Share Centre (an independent retail stockbroker) and Sharefunds (the Group’s investment management and fund administration subsidiary) has announced H1Jun16 interims. Performance in line with management expectations despite subdued trading backdrop ahead of the EU Referendum. Revenue slightly down from £7.4m to £7.4m. Underlying PBT of £110k from £608k.  Cash of £16.1m.  Trading has picked up post year end and  digital transformation continues.

 

Harvest minerals (HMI.L) 6.25p £5.9m

Independent Scoping Study has been completed for its Maximus Direct Application Natural Fertilizer Project. Preliminary economic assessment based on the current initial resource, which represents ~3% of the estimated mineralisation— Production of 100ktpa for 7 years, based on initial 883Kt Indicated JORC resource. Scenarios with sales prices of US$50/t and US$65/t generated NPV’s of US$15.0m and US$21.0m post tax, with a 10% WACC, and IRRs of 408.8% and 562.8% respectively .

 

Quantum Pharma (QP..L) 75p £93.75m

The service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors has successfully launched its licensed Glycopyrronium Bromide 1mg/5ml Oral Solution. The solution is licensed in adults as an add-on therapy in the treatment of peptic ulcers, which occur in the lining of the stomach or duodenum. It is the first unlicensed to licensed liquid formulation of this product in the UK . FYJAN17 forecasts suggest an 11x PE and 2.4% yield.

 

RTC Group (RTC.L) 65.5p £9.5m

RTC Group, whose  three principal trading subsidiaries engaged in the recruitment of human capital resources and the provision of managed services, reports H1Jun16 interims. Continuing revenues up 16% to £34.1m.  Basic earnings per share 2.83p (2015: 2.47p). Dividend up 10% to 1.1p. On FYDec16 forecasts the shares trade at 7.9x and yield 4.9%.

 

Arcontech Group (ARC.L) 0.41p £6.2m

The provider of products and services for real-time financial market data processing and trading, is pleased has announced FYJun16 results. Revenues flat at £2.1m.   Profit before tax of £302,329 (2015: £243,660) . Cash balance of £1,633,159 (2015: £1,069,755). Intends to implement share consolidation before proposing a dividend.  Mixed messages in outlook. Product investment has been strong. Sales cycles longer than hoped.  Low rates and Brexit tempering optimism.

 

Avacta Group (AVCT.L) 98.5p £67.35m

The developer of Affimer® biotherapeutics and research reagents, has announced that a collaborative development programme with Leeds University has been awarded a £3.8 million grant by the Medical Research Council to develop novel, rapid diagnostic tools incorporating Affimer reagents, to differentiate between viral and bacterial infections, and differentiate bacterial strains. This could be a powerful weapon in the fight against anti-microbial resistance.

 

Andalas Energy and Power (ADL.L) 1.16p £3.55m

The Indonesian focused oil and gas exploration company  has announced that Pertamina, Indonesia’s national energy company, has approved the Company’s Tuba Obi East proof of concept work programme.  The first step in this programme will be the recompletion of the existing TOE-1 well and production testing of the gas bearing Air Benakat Formation .

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.